查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862583

免疫療法市場依治療方法、適應症、給藥途徑、最終用戶和作用機制分類－2025-2032年全球預測

Immunotherapy Drugs Market by Therapy Type, Indication, Route Of Administration, End User, Mechanism Of Action - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫療法藥物市場將成長至 5,138.2 億美元，複合年成長率為 12.73%。

關鍵市場統計數據
基準年 2024 1969.6億美元
預計年份：2025年 2225.9億美元
預測年份 2032 5138.2億美元
複合年成長率 (%) 12.73%

本報告首先對現代免疫療法的現狀進行了簡要概述。報告闡明了研究範圍、目標和分析方法，旨在檢驗科學進展、臨床發展、監管動態和商業性趨勢。報告確立了後續分析的觀點，包括臨床療效趨勢、生產技術變革、供應鏈考量、監管要點以及相關人員的採納促進因素。透過事先設定這些參數，報告引導讀者了解將影響研究、臨床應用、生產規模化和市場進入等策略決策的相互關聯的主題。

調查方法，引言部分闡述如何綜合運用專家訪談、臨床資料庫審查、監管文件分析、專利分析以及真實世界證據，建構一個連貫的證據基礎。引言部分也概述了資料三角驗證的假設以及評估技術成熟度和實施準備度的標準。因此，引言部分明確地將本報告定位為決策者將科學研究機會與實際操作能力和政策現實結合的實用工具。

免疫療法的研究、生產、商業化和患者獲取途徑正經歷著變革性的轉變，這些轉變正在重新定義臨床模式和投資者的優先事項。

近年來，免疫療法領域發生了翻天覆地的變化，重塑了研究重點、商業化路徑以及患者接受治療的方式。精準細胞工程技術的進步，例如新一代受體設計和同種異體移植平台，正在催生更廣泛的治療概念和即用型產品。同時，疫苗平台、溶瘤載體和免疫調節劑的突破性進展正在融合為多模態療法，從而改變臨床開發策略的設計方式以及我們與監管機構的溝通方式。這些科學變革也伴隨著營運層面的變革：模組化生產、一次性技術和分散式生產模式正在重新定義生產力計畫和成本結構。

此外，資金籌措模式和投資者關注點正從早期藥物發現轉向可擴展的生產流程和持續臨床療效的驗證，這迫使企業建立策略聯盟並調整其市場推廣策略。患者獲取藥物的考量也在改變。隨著醫療系統在將複雜治療方法整合到標準治療路徑方面面臨挑戰，以及支付方要求採用按療效付費的模式，這些趨勢正在重新定義免疫療法生命週期中的價值創造，並迫使相關人員重新思考臨床設計、供應鏈韌性、報銷策略和長期商業化計劃。

2025年美國關稅對免疫療法供應鏈、生產製造、臨床試驗和病患取得的累積影響

美國關稅將於2025年生效，其累積影響將對整個免疫療法供應鏈、生產經濟和臨床運作造成複雜的壓力。進口試劑、特殊耗材、細胞處理設備和某些中間生技藥品的關稅相關成本增加，將直接對製造商和合約研發生產機構（CDMO）的運作構成不利影響。由於先進治療方法生產的許多環節仍然依賴全球採購，這些額外成本可能會促使企業進行策略性調整，例如重新評估供應商合約、提高垂直整合程度以及增加本地化生產以降低風險。因此，除了成本和監管方面的考慮外，地緣政治風險將在製造地的決策中發揮越來越重要的作用。

除了生產製造之外，關稅還會透過增加進口套件、低溫運輸物流和外包檢測服務的成本，影響臨床試驗營運的經濟效益。這可能導致試驗週期延長，因為申辦方需要尋找替代供應商並重新審核其資格。支付方和醫療系統也可能面臨上游成本壓力，進而影響高成本治療方法的籌資策略和實施路徑。為此，行業相關人員可能會優先考慮具有韌性的籌資策略，實現供應鏈多元化，盡可能投資國內生產能力，並積極與採購和政策相關人員溝通，以尋求豁免和緩解措施。最終，關稅不會改變免疫療法的科學潛力，但會重塑營運重點，並要求在生產、臨床和商業等各個環節進行戰術性調整。

針對治療方法方式、適應症群、給藥途徑、最終用戶以及臨床和商業規劃機制，提供可操作的細分洞察

深入理解市場區隔對於將研發策略與臨床需求和商業化路徑相匹配至關重要。在考慮治療方法類型時，市場涵蓋細胞療法、癌症疫苗、查核點抑制劑、細胞激素和溶瘤病毒療法。在細胞療法領域，CAR-T療法、NK細胞療法和TCR-T療法等亞類尤其重要，因為每種療法在生產、監管和給藥方面都面臨著獨特的挑戰。癌症疫苗分為樹突細胞疫苗、DNA疫苗和胜肽疫苗，它們在抗原選擇、佐劑需求和給藥方法方面存在差異。查核點抑制劑包括CTLA-4抑制劑、PD-1抑制劑和PD-L1抑制劑，每種抑制劑都有其自身的療效和毒性特徵，進而影響聯合治療策略。細胞激素療法（例如集落刺激因子、干擾素和白細胞介素）作為免疫反應的調節劑和聯合治療的組成部分，繼續發揮重要作用。溶瘤病毒療法（包括基於腺病毒、皰疹病毒和呼腸孤病毒的平台）在載體設計、生產控制措施和免疫分析方面有其獨特的考慮因素。

從適應症角度來看，將癌症細分為血液系統惡性腫瘤、乳癌、肺癌和黑色素瘤，可以揭示不同的臨床路徑和應用趨勢。血液系統癌症亞型，如急性淋巴性白血病、急性骨髓性白血病、慢性淋巴性白血病和淋巴瘤，需要量身訂做的細胞療法和免疫調節策略。乳癌根據荷爾蒙受體陽性或三陰性進行分類，這反映了需要採用不同的生物標記主導策略和聯合治療。肺癌分為非小細胞肺癌和小細胞肺癌，會影響標靶選擇和試驗設計。同時，黑色素瘤的不同類型，例如皮膚黑色素瘤和葡萄膜黑色素瘤，表現出不同的免疫反應性。給藥途徑（腫瘤內、靜脈注射、皮下）的選擇直接影響供應鏈需求、臨床基礎設施和以病人為中心的照護模式。最終用戶，例如醫院、腫瘤診所和專科治療中心，會根據自身設施容量、臨床醫生經驗和報銷體系的不同，以不同的速度採用治療方法。此外，作用機制——分為主動免疫療法、聯合治療和被動免疫療法——是策略優先排序的核心。主動療法，例如癌症疫苗和溶瘤病毒療法，著重於誘導內源性免疫反應；而被動療法，例如過繼性細胞療法、查核點抑制劑和單株抗體，則依賴外源性效應因子的遞送或抑制免疫抑制路徑。總而言之，這些細分觀點指南優先研發路徑、臨床試驗設計和客製化商業化策略的製定，這些策略既體現了科學的細微差別，也反映了醫療服務的實際情況。

重點區域的採用趨勢、基礎設施發展、監管環境和市場進入的區域性洞察

區域趨勢正在影響全球範圍內的療法採納路徑、基礎設施準備、監管參與以及市場進入策略。在美洲，我們看到先進治療方法的進展日益加速，尤其是在那些融合了學術領導、生產製造專長和支付者合作的卓越中心。這些生態系在支持快速臨床轉化的同時，也凸顯了將高度複雜的治療方法整合到常規診療路徑中，以及與支付方協商基於價值的合作安排等切實可行策略的必要性。

在歐洲、中東和非洲地區，監管協調工作、國家健保體係以及多元化的醫療服務體系造就了廣泛的應用環境。細胞和基因療法的生產能力建設以及本地臨床專業知識在不同地區差異顯著，因此需要量身定做的打入市場策略、區域生產夥伴關係以及靈活的定價方法。在亞太地區，生物技術的快速投資、不斷擴大的臨床試驗活動以及國內生產能力的擴張正在推動區域創新，即便監管路徑日趨成熟。在所有地區，基礎設施建設的進展，包括符合GMP標準的設施、低溫運輸物流和專業臨床中心，將是決定應用速度的關鍵因素，相關人員需要將區域策略與當地的監管和醫保實際情況相協調，以最佳化患者的治療機會。

對管道配置、策略合作夥伴關係、製造能力、監管地位和商業化路徑競爭考察

免疫療法領域的競爭格局呈現出多元化的特點，參與者包括成熟的製藥公司、生物技術創新者、專業契約製造和學術聯盟。擁有差異化平台、將專有生物學見解與可擴展生產優勢相結合的公司處於主導地位，而那些致力於產生可靠臨床證據並衡量真實世界療效的機構則與支付方和臨床醫生建立了長期互信的合作關係。策略合作、授權授權和有針對性的收購仍然是加速獲取互補能力（例如載體生產、細胞處理自動化和伴隨診斷）的關鍵手段。

隨著主要企業不斷鞏固產能、採用自動化技術並與專業的合約研發生產機構（CDMO）合作，生產能力正日益成為競爭優勢的重要支柱。監管定位以及與監管機構的積極溝通對於制定核准途徑至關重要，尤其對於新型聯合治療和細胞療法產品而言更是如此。此外，能夠建立清晰的衛生經濟學論點並及早與價值評估機構接洽的企業，更有可能獲得醫保報銷並廣泛應用。最終，競爭成功不僅取決於單一領域的優勢，更取決於科學、生產、監管策略和醫保溝通等方面的整合執行。

產業領導者提出切實可行的策略建議，以加速臨床開發、增強生產韌性並確保患者公平獲得治療。

產業領導者應採取一系列優先策略行動，將科學進步與永續的病患用藥途徑連結起來。首先，各機構應透過在發現階段早期就納入製程開發，並檢驗可擴展的、品質源自於設計（QbD）的生產方法，使臨床開發與可生產性保持一致。這將降低下游風險，並實現更可預測的監管互動。其次，相關人員應投資加強供應鏈韌性，具體措施包括供應商多元化、評估替代來源以及探索區域製造夥伴關係，以減輕地緣政治和關稅相關干擾的影響。

第三，企業應儘早與支付者、醫療服務提供者和病患權益組織合作，共同製定包含真實世界治療結果和可行支付模式的價值驗證框架。第四，與技術提供者、診斷開發商和臨床網路建立策略聯盟，可以加快臨床應用速度並擴大患者群體。第五，企業應優先考慮資料基礎設施和互操作系統，以收集長期治療結果和安全性訊號。這將有助於醫保報銷談判，並為產品的迭代改進提供資訊。最後，企業應促進細胞療法生產、監管事務和病患服務領域的人才培養，以確保組織能力與商業性目標保持同步。綜上所述，這些建議為將科學突破轉化為臨床和商業性可行的治療方法提供了切實可行的藍圖。

採用嚴謹的混合方法調查方法，包括一手訪談、臨床資料庫審查、監管分析和真實世界證據綜合。

本調查方法採用混合方法，將質性專家訪談與臨床註冊資料、監管文件和科學文獻的量化分析結合。主要研究包括與臨床研究人員、生產企業高管、監管專家、支付方代表和患者權益倡導團體進行結構化諮詢，以揭示實際應用中的挑戰和推動技術應用的因素。次要研究則包括同行評審期刊、臨床試驗註冊數據、監管指導文件、專利申請和公開資訊，以檢驗趨勢並進行結果的三角驗證。

我們的分析方法包括對訪談結果進行主題綜合分析、對監管路徑進行比較分析以及繪製生產和供應連結口圖。我們基於真實世界證據的分析重點在於治療模式、取得障礙以及核准後安全性監測，前提是能夠取得公開資料。在整個過程中，我們專注於透明地記錄資料來源，謹慎解讀可能存在偏差的資料集，並在專家支援下反覆驗證檢驗，以提高結論的穩健性和實際應用價值。

對研究結果、策略意義和優先行動進行關鍵性綜合分析，這些內容支撐著免疫療法創新和可及性的未來發展軌跡。

總之，免疫療法在科學和實踐層面持續發展，需要相關人員將技術可能性與實際執行結合，才能真正造福患者。從精密的細胞工程和模組化製造到先進的疫苗和溶瘤病毒平台，科學創新正在拓展治療選擇，但要將其轉化為常規治療，則需要穩健的生產製造、數據驅動的報銷策略，以及與區域基礎設施和法規結構的協調一致。關稅和地緣政治因素帶來的成本壓力，使得供應鏈多角化和在地化工作更加緊迫，凸顯了戰略遠見的重要性。

隨著該領域的不斷發展，整合跨職能能力的機構將更易取得成功：將早期研發與生產可行性相結合，與支付方和醫療服務提供方合作以展現價值，建立夥伴關係以加速商業化，並投資數據系統以記錄長期療效。擴大患者群體的可及性不僅需要科學的努力，還需要營運、策略和協作。現在就採取行動加強這些方面的經營團隊和臨床領導者，將更有能力將免疫療法的創新轉化為切實有效的、公平的患者照護改善。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 快速應用靶向固態腫瘤腫瘤抗原的雙特異性抗體
  • 拓展CAR-T療法的應用範圍：從骨髓惡性腫瘤到固態腫瘤
  • 引入免疫查核點抑制劑生物相似藥，以實現新興市場的可負擔性
  • 開發能夠促進T細胞浸潤抗藥性腫瘤的腫瘤微環境調節劑
  • 結合基因測序和人工智慧驅動的表位預測的個人化新抗原疫苗平台
  • 引入將溶瘤病毒與PD-1和CTLA-4抑制劑結合的聯合治療
  • 擴大同種異體現成天然去活化細胞產品的生產規模，簡化生產流程
  • 新一代IL-2和IL-15細胞激素療法安全性得到提升，其監管核准已加快。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：免疫治療方法藥物市場

  • 過繼性細胞療法
    • CAR-T療法
    • NK細胞療法
    • Tcr-T療法
  • 癌症疫苗
    • 樹突細胞疫苗
    • DNA疫苗
    • 胜肽疫苗
  • 查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 細胞激素
    • 集落刺激因子
    • 干擾素
    • 白細胞介素
  • 溶瘤病毒療法
    • 基於腺病毒的
    • 皰疹病毒
    • 基於呼腸孤病毒

第9章：以適應症分類的免疫療法藥物市場

  • 血癌
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
    • 淋巴瘤
  • 乳癌
    • 荷爾蒙受體陽性
    • 三重否定
  • 肺癌
    • 非小細胞肺癌
    • 小細胞肺癌
  • 黑色素瘤
    • 皮膚黑色素瘤
    • 葡萄膜黑色素瘤

第10章：按給藥途徑分類的免疫療法市場

  • 瘤內給藥
  • 靜脈注射
  • 皮下注射

第11章 以最終用戶分類的免疫療法藥物市場

  • 醫院
  • 腫瘤診所
  • 專業中心

第12章：免疫療法藥物市場依作用機制分類

  • 主動免疫療法
    • 癌症疫苗
    • 溶瘤病毒療法
  • 聯合治療
  • 被動免疫療法
    • 過繼性細胞療法
    • 查核點抑制劑
    • 單株抗體

第13章：各地區免疫療法藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的免疫療法藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國免疫療法藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca PLC
    • Novartis AG
    • Johnson & Johnson
    • Gilead Sciences, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Amgen Inc.
Product Code: MRR-521BAA36EBB6

The Immunotherapy Drugs Market is projected to grow by USD 513.82 billion at a CAGR of 12.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 196.96 billion
Estimated Year [2025] USD 222.59 billion
Forecast Year [2032] USD 513.82 billion
CAGR (%) 12.73%

This report opens with a concise framing of the contemporary immunotherapy landscape, clarifying the scope, objectives, and analytical approach taken to examine scientific advances, clinical evolution, regulatory developments, and commercial dynamics. It establishes the lenses through which subsequent analysis is presented, including clinical efficacy trends, manufacturing technology shifts, supply chain considerations, regulatory touchpoints, and stakeholder adoption drivers. By setting these parameters early, the narrative guides readers through interconnected themes that inform strategic decisions across research, clinical deployment, manufacturing scale-up, and market access.

Methodologically, the introduction explains the integration of primary expert interviews, clinical database reviews, regulatory documentation, patent analysis, and real-world evidence to build a coherent evidence base. It also outlines assumptions on data triangulation and the criteria used to evaluate technological maturity and adoption readiness. In doing so, the introduction positions the report as a pragmatic tool for decision-makers seeking to align scientific opportunity with operational capability and policy realities.

Transformative shifts reshaping immunotherapy research, manufacturing, commercialization and patient access that redefine clinical paradigms and investor priorities

Recent years have witnessed transformative shifts that are reshaping research priorities, commercialization pathways, and the delivery of immunotherapies to patients. Advances in precision cell engineering, such as next-generation receptor designs and allogeneic platforms, are enabling broader therapeutic concepts and the potential for off-the-shelf products. Concurrently, breakthroughs in vaccine platforms, oncolytic vectors, and immune modulators are being combined in multi-modal regimens, changing how clinical development strategies are designed and how regulatory engagement is approached. These scientific shifts are complemented by operational changes: modular manufacturing, single-use technologies, and distributed production models are redefining capacity planning and cost structures.

Moreover, financing models and investor sentiment have evolved from an emphasis on early discovery to validation of scalable manufacturing and durable clinical benefit, prompting companies to form strategic alliances and adapt go-to-market strategies. Patient access considerations are also shifting as health systems grapple with the integration of complex therapies into standard care pathways and as payers seek outcomes-linked approaches. Taken together, these developments redefine where value is created along the immunotherapy lifecycle and require stakeholders to rethink clinical design, supply chain resilience, reimbursement strategy, and long-term commercialization planning.

Cumulative implications of United States tariffs enacted in 2025 for immunotherapy supply chains, manufacturing, clinical trials, and patient access

The cumulative effect of United States tariff measures enacted in 2025 introduces a complex set of pressures across immunotherapy supply chains, manufacturing economics, and clinical operations. Tariff-related cost increases on imported reagents, specialized consumables, cell processing equipment, and certain biologic intermediates create direct operational headwinds for manufacturers and contract development and manufacturing organizations. Since many components of advanced therapy manufacturing remain globally sourced, these added costs can prompt strategic shifts including re-evaluation of supplier contracts, increased vertical integration, and accelerated localization efforts to mitigate exposure. In turn, manufacturing footprint decisions will increasingly weigh geopolitical risk alongside cost and regulatory considerations.

Beyond manufacturing, tariffs influence the economics of clinical trial operations by raising the cost of imported kits, cold-chain logistics, and outsourced laboratory services, which can extend timelines when sponsors seek alternate sources or requalify suppliers. Payers and health systems may also encounter upstream cost pressures that affect procurement strategies and adoption pathways for high-cost therapies. In response, industry stakeholders are likely to prioritize resilient sourcing strategies, diversify supplier bases, invest in domestic capacity where feasible, and engage proactively with procurement and policy stakeholders to clarify exemptions or mitigation mechanisms. Ultimately, while tariffs do not alter the scientific promise of immunotherapies, they reconfigure operational priorities and necessitate tactical adjustments across manufacturing, clinical, and commercial functions.

Actionable segmentation insights on therapy modalities, indication cohorts, administration routes, end users, and mechanisms for clinical and commercial planning

A nuanced understanding of segmentation is essential to align development strategies with clinical needs and commercial pathways. When considering therapy type, the landscape encompasses Adoptive Cell Therapy, Cancer Vaccines, Checkpoint Inhibitors, Cytokines, and Oncolytic Virus Therapy. Within Adoptive Cell Therapy, attention must be paid to subcategories such as CAR-T therapy, NK cell therapy, and TCR-T therapy because each presents distinct manufacturing, regulatory, and delivery challenges. Cancer Vaccines span dendritic cell vaccines, DNA vaccines, and peptide vaccines, which differ in antigen selection, adjuvant needs, and administration logistics. Checkpoint Inhibitors include CTLA-4 inhibitors, PD-1 inhibitors, and PD-L1 inhibitors, each with unique efficacy and toxicity profiles that shape combination strategies. Cytokine approaches, including colony stimulating factors, interferons, and interleukins, continue to play roles as modulators of immune response and as components of combination regimens. Oncolytic Virus Therapy, covering adenovirus-based, herpesvirus-based, and reovirus-based platforms, presents specific considerations around vector design, manufacturing containment, and immune profiling.

From an indication perspective, segmentation across blood cancers, breast cancer, lung cancer, and melanoma reveals divergent clinical pathways and adoption dynamics. Blood cancer subtypes such as acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and lymphoma each demand tailored cell therapy and immunomodulatory approaches. Breast cancer segmentation into hormone receptor positive and triple negative categories reflects distinct biomarker-driven approaches and combination needs. Lung cancer differentiation between non-small cell and small cell disease affects target selection and trial design, while melanoma contexts such as cutaneous and uveal melanoma diverge in immune responsiveness. Route of administration considerations-intratumoral, intravenous, and subcutaneous-directly influence supply chain requirements, clinical infrastructure, and patient-centered care models. End users including hospitals, oncology clinics, and specialized centers will adopt therapies at different paces depending on capacity, clinician expertise, and reimbursement mechanisms. Finally, mechanisms of action framed as active immunotherapy, combination therapies, and passive immunotherapy are central to strategic prioritization: active approaches such as cancer vaccines and oncolytic virus therapy focus on inducing endogenous responses, whereas passive strategies like adoptive cell therapy, checkpoint inhibitors, and monoclonal antibodies rely on exogenous effector delivery or inhibition of inhibitory pathways. Collectively, these segmentation lenses inform prioritized development pathways, clinical trial design, and tailored commercialization strategies that reflect both scientific nuance and healthcare delivery realities.

Regional insights on adoption dynamics, infrastructure readiness, regulatory landscapes, and market access considerations across major global regions

Regional dynamics shape adoption trajectories, infrastructure readiness, regulatory engagement, and market access approaches across the globe. In the Americas, advanced therapy accelerators are visible in centers of excellence that combine academic leadership, manufacturing know-how, and payer engagement. These ecosystems support rapid clinical translation but also highlight the need for pragmatic strategies to integrate high-complexity therapies into routine care pathways and to negotiate value-based arrangements with payers.

In Europe, Middle East & Africa, regulatory harmonization efforts, national reimbursement frameworks, and diverse healthcare delivery systems create a spectrum of adoption environments. Capacity building for cell and gene therapy manufacturing and on-site clinical expertise varies widely, prompting tailored market entry strategies, regional manufacturing partnerships, and adaptive pricing approaches. In Asia-Pacific, rapid investment in biotechnology, growing clinical trial activity, and expanding domestic manufacturing capabilities are driving significant local innovation, even as regulatory pathways mature. Across all regions, infrastructure readiness-including GMP-compliant facilities, cold-chain logistics, and specialized clinical centers-remains a decisive factor in the pace of adoption, and stakeholders must align regional strategies with local regulatory and reimbursement realities to optimize patient access.

Competitive company insights examining pipeline composition, strategic alliances, manufacturing capabilities, regulatory positioning and commercialization pathways

Competitive dynamics in the immunotherapy space are characterized by a diverse mix of established pharmaceutical companies, biotechnology innovators, specialized contract manufacturers, and academic consortia. Companies with differentiated platforms that combine proprietary biology with scalable manufacturing advantage are positioned to lead, while organizations that invest in robust clinical evidence generation and real-world outcome measurement build long-term credibility with payers and clinicians. Strategic alliances, licensing deals, and targeted acquisitions remain central instruments for accelerating access to complementary capabilities such as vector production, cell processing automation, and companion diagnostics.

Manufacturing capability is an increasingly visible axis of competitive differentiation as leaders secure capacity, adopt automation, and form partnerships with specialized contract development and manufacturing organizations. Regulatory positioning and proactive engagement with authorities to shape approval pathways, especially for novel combination regimens and cell-based products, are critical. Moreover, companies that develop clear health economics narratives and engage early with value-assessment bodies enhance their prospects for reimbursement and broader adoption. Ultimately, competitive success will hinge on integrated execution across science, manufacturing, regulatory strategy, and payer engagement rather than on single-domain strength alone.

Practical and actionable strategic recommendations for industry leaders to accelerate clinical development, manufacturing resilience, and equitable patient access

Industry leaders should adopt a prioritized set of strategic actions to translate scientific progress into sustainable patient access. First, organizations must align clinical development with manufacturability by embedding process development earlier in discovery phases and by validating scalable, quality-by-design manufacturing approaches. This reduces downstream risk and enables more predictable regulatory interactions. Second, stakeholders should invest in supply chain resilience by diversifying suppliers, qualifying alternate sources, and exploring regional manufacturing partnerships to mitigate geopolitical or tariff-related disruptions.

Third, firms should engage payers, providers, and patient advocacy groups early to co-develop value demonstration frameworks that incorporate real-world outcomes and feasible payment models. Fourth, forging strategic alliances with technology providers, diagnostics developers, and clinical networks can accelerate time-to-clinic and broaden access. Fifth, companies should prioritize data infrastructure and interoperable systems to capture long-term outcomes and safety signals, which supports reimbursement negotiations and informs iterative product improvement. Finally, leaders must cultivate workforce capabilities in cell therapy manufacturing, regulatory affairs, and patient services to ensure that organizational capacity matches commercial ambition. Together, these recommendations create a practical roadmap for converting scientific breakthroughs into clinically and commercially viable therapies.

Rigorous mixed-methods research methodology integrating primary interviews, clinical database review, regulatory analysis, and real-world evidence synthesis

The research methodology employs a mixed-methods approach that integrates qualitative expert interviews with quantitative review of clinical registries, regulatory filings, and scientific literature. Primary research included structured consultations with clinical investigators, manufacturing leaders, regulatory specialists, payer representatives, and patient advocates to surface real-world challenges and adoption drivers. Secondary sources encompassed peer-reviewed journals, clinical trial registries, regulatory guidance documents, patent filings, and public disclosures to validate trends and triangulate insights.

Analytic techniques included thematic synthesis of interview findings, comparative analysis of regulatory pathways, and mapping of manufacturing and supply chain touchpoints. Real-world evidence analyses focused on treatment patterns, utilization barriers, and post-approval safety monitoring where publicly available data permitted. Throughout, emphasis was placed on transparent documentation of data provenance, conservative interpretation of datasets prone to bias, and iterative validation of conclusions with domain experts to enhance robustness and practical relevance.

Conclusive synthesis of findings, strategic significance, and priority actions underscoring the future trajectory of immunotherapy innovation and access

In conclusion, immunotherapy continues to advance across scientific and operational dimensions, and stakeholders must synthesize technological promise with pragmatic execution to realize patient impact. Scientific innovations-ranging from refined cell engineering and modular manufacturing to sophisticated vaccine and oncolytic platforms-are expanding therapeutic options, yet their translation into routine care depends on resilient manufacturing, data-driven reimbursement strategies, and regional alignment with infrastructure and regulatory frameworks. Tariff-driven cost pressures and geopolitical considerations add urgency to supply chain diversification and localization efforts, underscoring the need for strategic foresight.

As the field evolves, success will favor organizations that integrate cross-functional capabilities: aligning early development with manufacturing feasibility, engaging payers and providers to demonstrate value, building partnerships to accelerate commercialization, and investing in data systems that capture long-term outcomes. The pathway to broader patient access is not solely scientific; it is operational, strategic, and collaborative. Executives and clinical leaders who act now to strengthen these dimensions will be best positioned to translate immunotherapy innovation into meaningful, equitable improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of bispecific antibodies targeting dual tumor antigens in solid tumors
  • 5.2. Expansion of CAR-T therapies beyond hematologic malignancies into solid tumor indications
  • 5.3. Integration of immune checkpoint inhibitor biosimilars to improve affordability across emerging markets
  • 5.4. Development of tumor microenvironment modulators to enhance T-cell infiltration in resistant tumors
  • 5.5. Personalized neoantigen vaccine platforms combining genomic sequencing with AI-driven epitope prediction
  • 5.6. Implementation of combination therapies integrating oncolytic viruses with PD-1 and CTLA-4 inhibitors
  • 5.7. Growth of allogeneic off-the-shelf natural killer cell products to streamline manufacturing timelines
  • 5.8. Regulatory approvals accelerating for next-generation IL-2 and IL-15 cytokine therapies with improved safety profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immunotherapy Drugs Market, by Therapy Type

  • 8.1. Adoptive Cell Therapy
    • 8.1.1. Car-T Therapy
    • 8.1.2. Nk Cell Therapy
    • 8.1.3. Tcr-T Therapy
  • 8.2. Cancer Vaccines
    • 8.2.1. Dendritic Cell Vaccines
    • 8.2.2. Dna Vaccines
    • 8.2.3. Peptide Vaccines
  • 8.3. Checkpoint Inhibitors
    • 8.3.1. Ctla-4 Inhibitors
    • 8.3.2. Pd-1 Inhibitors
    • 8.3.3. Pd-L1 Inhibitors
  • 8.4. Cytokines
    • 8.4.1. Colony Stimulating Factors
    • 8.4.2. Interferons
    • 8.4.3. Interleukins
  • 8.5. Oncolytic Virus Therapy
    • 8.5.1. Adenovirus Based
    • 8.5.2. Herpesvirus Based
    • 8.5.3. Reovirus Based

9. Immunotherapy Drugs Market, by Indication

  • 9.1. Blood Cancer
    • 9.1.1. Acute Lymphoblastic Leukemia
    • 9.1.2. Acute Myeloid Leukemia
    • 9.1.3. Chronic Lymphocytic Leukemia
    • 9.1.4. Lymphoma
  • 9.2. Breast Cancer
    • 9.2.1. Hormone Receptor Positive
    • 9.2.2. Triple Negative
  • 9.3. Lung Cancer
    • 9.3.1. NonSmallCell Lung Cancer
    • 9.3.2. SmallCell Lung Cancer
  • 9.4. Melanoma
    • 9.4.1. Cutaneous Melanoma
    • 9.4.2. Uveal Melanoma

10. Immunotherapy Drugs Market, by Route Of Administration

  • 10.1. Intratumoral
  • 10.2. Intravenous
  • 10.3. Subcutaneous

11. Immunotherapy Drugs Market, by End User

  • 11.1. Hospitals
  • 11.2. Oncology Clinics
  • 11.3. Specialized Centers

12. Immunotherapy Drugs Market, by Mechanism Of Action

  • 12.1. Active Immunotherapy
    • 12.1.1. Cancer Vaccines
    • 12.1.2. Oncolytic Virus Therapy
  • 12.2. Combination Therapies
  • 12.3. Passive Immunotherapy
    • 12.3.1. Adoptive Cell Therapy
    • 12.3.2. Checkpoint Inhibitors
    • 12.3.3. Monoclonal Antibodies

13. Immunotherapy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Immunotherapy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Immunotherapy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Merck & Co., Inc.
    • 16.3.2. Bristol-Myers Squibb Company
    • 16.3.3. F. Hoffmann-La Roche Ltd
    • 16.3.4. AstraZeneca PLC
    • 16.3.5. Novartis AG
    • 16.3.6. Johnson & Johnson
    • 16.3.7. Gilead Sciences, Inc.
    • 16.3.8. Pfizer Inc.
    • 16.3.9. Sanofi S.A.
    • 16.3.10. Amgen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. IMMUNOTHERAPY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. IMMUNOTHERAPY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. IMMUNOTHERAPY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TCR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CYTOKINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HERPESVIRUS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BLOOD CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY TRIPLE NEGATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY NONSMALLCELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SMALLCELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CUTANEOUS MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY UVEAL MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY SPECIALIZED CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL IMMUNOTHERAPY DRUGS MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL IMMUNOTHERAP